Aflibercept 8 mg shows comparable IOP safety to 2 mg through 96 weeks
A pooled analysis of the phase 3 PULSAR and PHOTON trials found that aflibercept 8 mg, administered at a higher injection volume than aflibercept 2 mg, was not associated with increased long-term intraocular pressure (IOP) or glaucoma-related safety concerns through 96 weeks in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).... ...